01—Abstract
Summary
Summary of the 8-K filed September 23, 2025. Cited figures are marked; the original filing is the authoritative source.
McKesson (MCK) used its September 23, 2025 Investor Day to raise and narrow its fiscal 2026 Adjusted EPS guidance to $38.05a–$38.55, up from $37.10–$37.90.
The midpoint rises by roughly $1.05b, or about 2.8%, signaling management confidence in current operating momentum. The company also raised its long-term Adjusted EPS growth target to 13%–16%, from 12%–14%, citing strength in oncology, multispecialty, and biopharma solutions along with operating leverage and capital deployment discipline. The company is also reorganizing its reporting structure, which was announced September 18, 2025.
It introduced new long-term Adjusted Segment Operating Profit growth targets: North American Pharmaceutical at 5%c–8%, Oncology & Multispecialty at 13%–16%, and Prescription Technology Solutions at 10%–13%. The filing also references the planned separation of the Medical-Surgical Solutions segment into an independent company and the sale of its Norway businesses. These portfolio moves are central to the new segment framework, and investors will want to watch how they affect margins and capital allocation.
The filing is furnished under Item 7.01 (Regulation FD) and is not deemed filed under the Exchange Act. GAAP guidance is not provided, because LIFO adjustments, litigation contingencies, and restructuring or impairment charges are difficult to forecast.
Investors should therefore focus on the non-GAAP framework and the risk factors cited, including opioid-related litigation, which remains a material exposure. The next catalyst is the Q2 fiscal 2026 earnings release on November 5, 2025.
02—Key points
Key Highlights
- Fiscal 2026 Adjusted EPS guidance raised and narrowed to $38.05–$38.55 from $37.10–$37.90, a midpoint increase of about 2.8%.
- Long-term Adjusted EPS growth target increased to 13%–16% from 12%–14%.
- New segment-level long-term targets: North American Pharmaceutical 5%–8%, Oncology & Multispecialty 13%–16%, Prescription Technology Solutions 10%–13%.
- Organizational restructuring announced September 18, 2025, aimed at sharper growth focus, transparency, and capital allocation.
- Planned separation of the Medical-Surgical Solutions segment into an independent company and sale of Norway businesses.
- No GAAP guidance provided; management cites inability to forecast LIFO, litigation, and restructuring items without unreasonable effort.
- Next catalyst: Q2 fiscal 2026 results on November 5, 2025, with a 4:30 PM ET call; investor conferences follow in November, December, and January.
03—Questions
Frequently Asked Questions
How much did McKesson raise its fiscal 2026 earnings guidance?
McKesson raised and narrowed its fiscal 2026 Adjusted EPS guidance to $38.05–$38.55 from $37.10–$37.90. The midpoint moves from $37.50 to $38.30, an increase of about $0.80, or roughly 2.1%. This is based on the midpoints of the two ranges, so the exact percentage may differ slightly from the company's own calculation.
What is McKesson's new long-term growth target?
The long-term Adjusted EPS growth target is now 13%–16%, up from 12%–14%. Management attributes the increase to its oncology, multispecialty, and biopharma platforms, along with operating leverage and efficient capital deployment.
Why does McKesson not provide GAAP guidance?
The company says it cannot reconcile forward-looking non-GAAP measures to GAAP without unreasonable effort. LIFO inventory adjustments, litigation gains and losses, restructuring and impairment charges, and other items are difficult to predict, so GAAP results could vary materially from any estimate.
What does the Medical-Surgical separation mean for investors?
McKesson intends to separate its Medical-Surgical Solutions segment into an independent company and is also selling its Norway businesses. The filing does not provide transaction details, timing, or financial impact, so investors should review the Investor Day presentation and future filings for those specifics.
What are the key risks highlighted in the filing?
The release cites risks including costly legal disputes and settlements tied to opioid distribution, changes in healthcare regulation and reimbursement, cybersecurity incidents, supplier relationship changes, customer defaults, and competition. Opioid-related litigation is specifically flagged as a material exposure.
04—Continue